UCB finds buyer for US generics business despite methylphenidate uncertainties
This article was originally published in Scrip
Executive Summary
Belgian pharma company UCB S.A. has finally found a buyer for its US generics business Kremers Urban Pharmaceuticals Inc., after a deal with private equity firms Advent International and Avista Capital Partners fell through last year. Lannett Company Inc. will pay the Belgian firm $1.23bn in cash plus certain contingent payments.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.